• ● Faculty and Staff
Xing-Jie Liang
Deputy Director of the Laboratory of Biological Effects of Nanomaterials and Nanosafety
Academic title:
Postal Code:
Subject categories:
Mailing Address:
No.11,Beiyitiao Zhongguancun Beijing,china


Dr. Xing-Jie Liang got his Ph.D at National Key Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences. He finished his postdoc with Dr. Michael M. Gottesman (Deputy Director of NIH, USA and Academician member of US national academy of sciences) for 5 years at Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Then, he worked as a Research Fellow at Surgical Neurology Branch, NINDS (National Institute of Neurological Diseases and Strokes, NIH) for 2 years. In 2007, he was an Assistant professor at Department of Radiology, School of Medicine, Howard University. Dr. Liang currently is deputy director of Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences and Lab Chief of Laboratory of Controllable Nanopharmaceuticals, National Center for Nanoscience and Technology of China. He is also leading a group on nanopharmaceuticals at the CAS Center for Excellence in Nanoscience and Chief Lecture Professor of Nanobiology at University of Chinese Academy of Sciences.


Dr. Xing-Jie Liang is current editor-in-chief ofCurrent Drug Delivery, deputy Editor-in-Chief of Biophysics Reports and Associate Editor of Biomaterials, Advisory Board Member of ACS Nano. He is also current editorial board member of Bioconjugate Chemistry, Biomaterials Research,Theranosticsand guest editor of Biotechnology Advances.


Dr. Liang was awarded with the Distinguished Young Scientists Grant by National Natural Science Foundation in 2012 and honored with the People's Republic of China State Council Special Allowance in 2010 as well as National Youth Science and technology innovation leader in 2017. Prof. Liang published over 280 peer-reviewed papers including articles in “Nature Nanotechnology, PNAS, Nano Letter, Advanced Materials, Cancer Research” with citations over 13000 until 2018.


The current researches include three topics ongoing in the laboratory.

1.     Nanopharmaceutical techniques: FDA approved materials developed with nanotechnologies to improve the bioavailability and therapeutic efficacy as well as to decrease systemic toxicity of chemocompounds or bio-drugs (genes or proteins) by targeted delivery and controllable release;

2.     Nanobiotechnology: Nanostructures to overcome the adaptive treatment tolerance (ATT) in vitro and in vivo:

3.     Nanoplatforms: Nanoscale DDS for Chemo-/Gene-Therapy; Nano-AIE for Pharmadynamic/Kinetic evaluation; Nanovaccine for immunological enhance of neoantigen:  

     In addition, another topic on nanoimaging is another interested field in his group.

4.     Nanoimaging and Nanodiagnosis:  Nanopharmaceuticals ADMET in vivo by various techniques (Nano SPECT/CT, Acoustic ultrasound, In vivo Imaging, MRI, Bio-TEM etc)


Prof. Liang has successfully developed “Injectable Nanomicelles Powders with Irinotecan” approved with CFDA for clinical trials with China Resources Pharmaceutical Group. His researches are to develop nanopharmaceuticals for clinical trials and transfer FDA-certified licenses to pharmaceutical companies for production. This mission is from his interests in elucidating mechanisms to improve nanomedicinal bioavailability by nanotechnology in vivo, and developing novel strategies to increase therapeutic effect on cancers and infectious- or immune- diseases. Improved drug delivery efficiency for prevention/treatment of different diseases are under investigation in Dr. Liang's lab based on understanding of basic physio-chemical and biological processes of nanodrugs. Most protocols are employed for delivering therapeutic molecules to actively target cells or tissues in vivo to enhance drug safety and efficacy.


nanomedicine and nanopharmaceuticals


2004 2005 and 2006 "Fellows Award for Research Excellence" National Institute of Health, USA. “Special Government Allowances” by Department of State, 2011; “National Distinguished Young Scholars” by NSFC; “Young Pharmaceutics Scholar” by CPA, 2012; “Outstanding Research Award” to hundred elite researcher of CAS, 2013;  “Inspection Improve Award” by General Administration of Quality Supervision, Inspection and Quarantine of the People’s Republic of China, 2014.  CAS-BHHB Award 2015; SABIC-CAS Award 2016 and 2018;  Biomaterials Outstanding Paper Award, 2016; National Youth Science and technology innovation leader, 2017; Tianjin Natural Science Award First Prize 2018


Representative research articles as corresponding author *


1.        Gong N. et al. Liang X.-J.* Carbon dot-supported atomically-dispersed gold (CAT-g) as a mitochondrial oxidative stress amplifier for cancer treatment. Nature Nanotechnology. 2018. DOI: 10.1038/s41565-019-0373-6 (in press)

2.        Zhang T, et al. Liang XJ* Fluorinated Oligoethylenimine Nanoassemblies for Efficient siRNA-Mediated Gene Silencing in Serum-Containing Media by Effective Endosomal Escape. Nano Letter. 2018. 18(10):6301-6311.

3.        Zhao Y, et al. Liang XJ*. Spatiotemporally Controllable Peptide-based Nanoassembly in Single Living Cells for a Biological Self-portrait. Advanced Materials 2017. 29,1601128.

4.        Xue, X.; et al.  Liang, X. J*. Aggregated single-walled carbon nanotubes attenuate the behavioural and neurochemical effects of methamphetamine in mice. Nature Nanotechnology 2016, 11 (7), 613-620.

5.        Wei, T.; et al.  Liang, X.J*. Anticancer drug nanomicelles formed by self-assembling amphiphilic dendrimer to combat cancer drug resistance. PNAS. (Proc Natl Acad Sci U S A.).  2015. 112 (10): 2978-2983. 

6.        Xue, X.; et al.  Liang, X. J*. Single-walled carbon nanotubes alleviate autophagic/lysosomal defects in primary glia from a mouse model of Alzheimer's disease. Nano Letters 2014, 14 (9), 5110-5117.

7.        Xue, X.; et al.  Liang, X. J*. Spatiotemporal drug release visualized through a drug delivery system with tunable aggregation-induced emission. Advanced Materials 2014, 26 (5), 712-7.

8.        Wei, T.; et al.  Liang, X. J.* Functionalized nanoscale micelles improve drug delivery for cancer therapy in vitro and in vivo. Nano Letters 2013, 13 (6), 2528-34.

9.        Huo, SD.; et al. Liang, X. J.* Superior penetration and retention behavior of 50nm gold nanoparticles in tumor. Cancer Research.  2013 73:319-330.

10.     Liang, X.J. * et al. Metallofullerene Nanoparticles Circumvent Tumor Resistance to Cisplatin by Reactivating Endocytosis.  PNAS. (Proc Natl Acad Sci U S A.).  2010. 107(16):7449-7454.

Representative review articles as corresponding author *:


1.        Yufei Wang, Yuxuan Zhang, Jinjin Wang, Xing-Jie Liang*. AIE fluorophores as imaging tools to explore biological fate of nano-drug delivery systems. Advanced Drug Delivery Review. DOI10.1016/j.addr.2018.12.004. (In press)

2.        Ningqiang Gong; Yuxuan Zhang; Zhen Zhang; Xianlei Li; Xing-Jie Liang*. Functional Nanomaterials Optimized to Circumvent Tumor Immunological Tolerance. Advanced Functional Materials. 2018. 1806087 (1-16)

3.        Xiao-Li Liu, Shizhu Chen, Huan Zhang, Jin Zhou, Hai-Ming Fan* and Xing-Jie Liang* Magnetic Nanomaterials for Advanced Regenerative Medicine: The Promise and Challenges. Advanced Materials. 2018. 12(4): e 1804922.

4.        Yuxuan Zhang,  Yufei Wang,  Jinjin Wang  and  Xing-Jie Liang*. Pharmaceutical Research and Development Improved with AIE-based Nanostructures. Materials Horizons, 2018, 5, 799 – 812.

5.        Yufei Wang, Juan Liu, Xiaowei Ma and Xing-Jie Liang* Nanomaterial-assisted sensitization of oncotherapy. Nano Research 2018. 11(6): 2932–2950. 

6.        Lu Liu, Weisheng Guo, Xing-Jie Liang*. Move to Nano-Arthrology: Targeted Stimuli-Responsive Nanomedicines Combat Adaptive Treatment Tolerance (ATT) of Rheumatoid Arthritis. Biotechnology Journal.  2018. 1800024 (1-14).

7.        Yifeng Wang , Lu Liu , Xue Xue , Xing-Jie Liang*. Nanoparticle-based drug delivery systems: What can they really do in vivo? F1000 Research. 2017. 6 (F1000 Faculty Rev):681 (doi: 10.12688/f1000research.9690.1)

8.        Xiaowei Ma, Ningqiang Gong, Lin Zhong, Xing-Jie Liang *. Future of Nanotherapeutics: Targeting the Cellular Sub-organelles. Biomaterials. 2016. 97: 10-21.

9.        Juan Liu, Yuran Huang, Anil Kumar, Aaron Tan, Shubin Jin, Anbu Mozhi, Xing-Jie Liang*. pH-Sensitive nano-systems for drug delivery in cancer therapy. Biotechnology Advances 2014.32(4): 693-710.

10.     Xiao-wei Ma, Yuliang, Zhao, Xing-Jie Liang*. Theranostic Nanoparticles engineered for Clinic and Pharmaceutics. Accounts of Chemical Research. 2011. 44(10): 1114–1122


Representative articles before working at nanocenter


1.        Liang, X. J.*, Shen, D.W., Yin, J.J., Aszalos, A., and Gottesman, M. M. SIRT1 contributes to cisplatin resistance in cancer cells by altering mitochondrial metabolism.  Molecular Cancer Research. 2008, 6(9):1499-1506.

2.        Liang, X.J., Choi, Y., Sackett, D.L. and Park, J.K.  Inhibition of stathmin enhances CCNU blocking glioma cell migration and invasion. Cancer Research. 2008, 68(13):5267-5272.

3.        Hall MD, Okabe M, Shen, DW, Liang, XJ, and Gottesman, MM. The Role of Cellular Accumulation in Determining Sensitivity to Platinum-Based Chemotherapy. Annual Review of Pharmacology and Toxicology. 200848: 495-535.

4.        Ngo.T.B*, Peng T., *, Liang X.J *., Akeju O., Pastorino S., Zhang W., Fine H.A., Maric D., Wen P.Y.,  Girolami U.D., Black P.M., Wu W.,  Shen R.F., Kang D.W., and Park J.K. The 1p encoded protein stathmin modulates the response of malignant gliomas to nitrosoureas. Journal of National Cancer Institute. 2007, 99: 639-652.

5.        Liang, X. J., Mukherjee, S., Shen, D. W., Maxfield, F. R. and Gottesman, M. M. Endocytic Recycling Compartments Altered in Cisplatin-Resistant Cancer Cells . Cancer Research. 2006, 66 (4): Feb 15; 2346-2353.

6.        Liang, X. J., Shen, D. W., Chen G. K., Wincovitch S. M., Garfield, S., and Gottesman, M. M. Trafficking and localization of platinum complexes in cisplatin-resistant cell lines monitored by fluorescence-labeled platinum.  Journal of Cellular Physiology. 2005, 202 (3): 635-641.

7.        Liang, X.J, Shen, D.W, and Gottesman, M.M. Down-regulation and altered localization of g-catenin in cisplatin-resistant adenocarcinoma cells.  Molecular Pharmacology. 2004 65 (5): 1217-1224.

8.        Liang, X.J, Shen, D.W, and Gottesman, M.M. A pleiotropic defect reducing drug accumulation in cisplatin-resistant cells.  Journal of Inorganic Biochemistry. 2004 (98) 1599-1606.

9.        Liang, X.J, Yin, J.J., Zhou, J.W., Wang, P. C., Taylor, B., Cardarelli, C., Kozar, M, Forte, R., Aszalos, A. and Gottesman, M. M. Changes in biophysical parameters of plasma membranes influence cisplatin resistance of sensitive and resistant epidermal carcinoma cells.  Experimental Cell Research. 2004, 293: 283-291.

10.     Liang, X. J., Shen, D. W., Garfield, S., and Gottesman, M. M.  Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistanct cancer cell lines.  Cancer Research. 2003, 63: 5909-5916. 

Book Chapters:

1.        Gottesman, M.M., Hall, M.D., Liang, X.J., and Shen, D.W.: Resistance to Cisplatin Results from Multiple Mechanisms in Cancer Cells. In Bonetti, A. Leone, R. Muggia, F. Howell, S.B. (Eds.): Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy: Molecular Mechanisms and Clinical Applications. Humana Press, Totowa, New Jersey, 2009, 83-88.

2.        Liang, X.J., Chen, C.Y., Zhao, Y.L., Wang, P.C. Circumventing tumor resistance to chemotherapy by nanotechnology. Multi-Drug Resistance in Cancer Series: Methods in Molecular Biology , Zhou, Jun (Ed.), Humana Publisher, New York, 2010; 596: 467-488.

3.        Tan, J., Liu, C., Hu, L., Wang, C and Liang, X.J. The State of the Science: a 5-Year Review on the Computer-Aided Design for Global Anti-AIDS Drug Development. HIV-infection - Impact, Awareness and Social Implications of living with HIV/AIDS, Eugenia Barros (Edited), 2011, INTECH open access publisher, ISBN978-953-307-343-9. 2011, 25-46.

4.        Liang, X.J.  Editing “Nanopharmaceuticals: Potential Application of Nanomaterials. (approx. 800pp) World Scientific Publication Press, New Jersey, 2012. ISBN: 978-981-436-866-7.

5.        Xue, X., Liang, X.J. Multifunctional Nanoparticles for Theranostics and Imaging. Nanomedicine: Nanostructure Science and Technology. Springer New York.  2014, pp 101-115.

6.        梁兴杰、 杨科妮、李盛亮、王重夕、金叔宾等。第6 纳米辅料的药学应用。阎锡蕴主编 科学出版社。2014. Page  281-336

7.        Huo, S., Cao, X., Hu, Z. and Liang, X.J. Gold Nanoparticles: A Novel and Promising Avenue for Drug Delivery. Chapter 2 in Section I?Nanomaterials for Drug Delivery. Biological and Pharmaceutical Application of Nanomaterials. Polina Prokopovich (eds.). CRC Press, Taylor & Francis Group. Florida. 2015, pp 39-53.

8.        Zhang T, Zhang C, Xing J, Xu J, Li C, Wang P and Liang XJ.  Multifuctional Dendrimers for Drug Nanocarriers. Chapter 10. Handbook of Research on Novel Approaches for Drug Delivery (ISSN: 2327-9354; eISSN: 2327-9370). 2016. P245-276.

9.        《医用材料概论》人民卫生出版社 全国生物医学工程(临床工程)专业教材。胡盛寿院士 中国医学科学院阜外医院院长 主编。 副主编:奚廷斐  孔德领  王琳。第二章 医用材料分类 第七节 医用纳米材料 梁兴杰编著

10.     Ruslan G. Tuguntaev, Ahmed Shaker Eltahan, Satyajeet S. Salvi, and Xing-Jie Liang*. Chapter 12. Drug Targeting: Principles and Applications. Apple Academic Press for the book Drug Delivery Approaches and Nanosystems, Vol I: Novel Drug Carriers. 2017. July 30, 2017 by Apple Academic Press. Reference - 425 Pages. ISBN 9781771885836 - CAT# N11892.

11.     全国科学技术名词审定委员会《生物物理学名词》,2018.。科学出版社。

Community service:
Chinese Society of Biophysics Chinese Pharmaceutical AssociationAmerican Association for Cancer ResearchAmerican Society for Cell BiologyAssociation of the International Union against CancerInternational Society of Nanomedicine

Commitment to research the situation:

1.“International Collaborative Nano-program of China and Finland”, 2008-2010.  2.“973 Program (National Key Science and Technology Plan)” of Chinese Ministry of Science and Technology, 2009-2013 Chief Scientist. 3. National Natural Science Foundation of China (Key Program)2014-2017 and 2017-2020,  Principal Investigator.  4. “863” program (National Program of Gene Therapy) of Chinese Ministry of Science and Technology, 2012-2016Program Investigator. 5. National Natural Science Foundation of China (National Distinguished Young Scholars Program)2013-2016,  Principal Investigator. 6. Strategic Piority Research Program of Chinese Academy of Sciences, 2014-2018, Chief Scientist of Nanopharmaceutical Program. 7. National Natural Science Foundation of China (Key Program)2017-2021 and NSFC-DFG grant 2018-2020, Principal Investigator.